124 related articles for article (PubMed ID: 35466456)
1. Novel developed HPLC analyses of [
Eryilmaz K; Bakar HE; Kilbas B
J Labelled Comp Radiopharm; 2022 Jun; 65(7):178-186. PubMed ID: 35466456
[TBL] [Abstract][Full Text] [Related]
2. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical.
Mercanoglu G; Zilbeyaz K; Arslan N
Curr Radiopharm; 2023; 16(1):38-43. PubMed ID: 35899954
[TBL] [Abstract][Full Text] [Related]
4. 153Sm-EDTMP and 177Lu-EDTMP are equally safe and effective in pain palliation from skeletal metastases.
Taheri M; Azizmohammadi Z; Ansari M; Dadkhah P; Dehghan K; Valizadeh R; Assadi M
Nuklearmedizin; 2018 Sep; 57(5):174-180. PubMed ID: 30267399
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
Kamaldeep ; Thapa P; Wanage G; Tervankar S; Kaisar S; Ranade R; Basu S; Das T; Banerjee S
Nucl Med Commun; 2021 Oct; 42(10):1076-1084. PubMed ID: 34528928
[TBL] [Abstract][Full Text] [Related]
6. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent.
Máthé D; Balogh L; Polyák A; Király R; Márián T; Pawlak D; Zaknun JJ; Pillai MR; Jánoki GA
Nucl Med Biol; 2010 Feb; 37(2):215-26. PubMed ID: 20152721
[TBL] [Abstract][Full Text] [Related]
7. The development and validation of a high performance liquid chromatography method to determine the radiochemical purity of [
van Andel L; Aalbersberg EA; Geluk-Jonker MM; Stokkel MPM; Beijnen JH; Hendrikx JJMA
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 May; 1171():122605. PubMed ID: 33740691
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
[TBL] [Abstract][Full Text] [Related]
9. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
10. Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle Application.
Bal C; Yadav MP; Ballal S
Clin Nucl Med; 2016 Aug; 41(8):e386-7. PubMed ID: 27187728
[TBL] [Abstract][Full Text] [Related]
11. Estimated human absorbed dose of ¹⁷⁷Lu-BPAMD based on mice data: Comparison with ¹⁷⁷Lu-EDTMP.
Yousefnia H; Zolghadri S; Shanehsazzadeh S
Appl Radiat Isot; 2015 Oct; 104():128-35. PubMed ID: 26163291
[TBL] [Abstract][Full Text] [Related]
12. A Specific HPLC Method to Determine Residual HEPES in [
Migliari S; Scarlattei M; Baldari G; Silva C; Ruffini L
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889351
[TBL] [Abstract][Full Text] [Related]
13. Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats.
Yousefnia H; Zolghadri S; Jalilian AR
J Med Phys; 2015; 40(2):102-8. PubMed ID: 26170557
[TBL] [Abstract][Full Text] [Related]
14.
Askari E; Harsini S; Vahidfar N; Divband G; Sadeghi R
Cancer Biother Radiopharm; 2021 Jun; 36(5):383-390. PubMed ID: 33259726
[No Abstract] [Full Text] [Related]
15. Comparative studies on the potential use of
Zakaly HMH; Mostafa MYA; Deryabina D; Zhukovsky M
Int J Radiat Biol; 2020 Jun; 96(6):779-789. PubMed ID: 32043915
[No Abstract] [Full Text] [Related]
16. Studies on the Labeling of Ethylenediaminetetramethylene Phosphonic Acid, Methylene Diphosphonate, Sodium Pyrophosphate and Hydroxyapatite with Lutetium-177 for use in Nuclear Medicine.
Abbasi IA
World J Nucl Med; 2015; 14(2):95-100. PubMed ID: 26097419
[TBL] [Abstract][Full Text] [Related]
17. ¹⁷⁷Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases.
Shinto AS; Shibu D; Kamaleshwaran KK; Das T; Chakraborty S; Banerjee S; Thirumalaisamy P; Das P; Veersekar G
J Nucl Med Technol; 2014 Mar; 42(1):55-61. PubMed ID: 24503346
[TBL] [Abstract][Full Text] [Related]
18. Preliminary results of biodistribution and dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
[TBL] [Abstract][Full Text] [Related]
19. Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid.
Meckel M; Bergmann R; Miederer M; Roesch F
EJNMMI Radiopharm Chem; 2017; 1(1):14. PubMed ID: 29564390
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [
Hooijman EL; Ntihabose CM; Reuvers TGA; Nonnekens J; Aalbersberg EA; van de Merbel JRJP; Huijmans JE; Koolen SLW; Hendrikx JJMA; de Blois E
EJNMMI Radiopharm Chem; 2022 Nov; 7(1):29. PubMed ID: 36333648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
